TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3392233

Group type: EXPERIMENTAL
Intervention: Nilvadipine 2 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nilvadipine 4 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nilvadipine 6 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Nilvadipine (all doses)
Number of subjects: 6
Study: 31008870

Group type: EXPERIMENTAL
Intervention: 0.05 μg/kg/min norepinephrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.5 μg/kg/min phenylephrine
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 0.04 IU/min vasopressin
Number of subjects: 40

Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 40
Study: 29248107

Group type: EXPERIMENTAL
Intervention: RPSA
Number of subjects: 311

Group type: COMPARATOR
Intervention: EVLA-RTF
Number of subjects: 311
Study: 26980809

Group type: EXPERIMENTAL
Intervention: Subcutaneous 300 µg GCSF before implantation
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no GCSF)
Number of subjects: 112
Study: 25536499

Group type: EXPERIMENTAL
Intervention: (S)-citalopram (10mg/d)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: (R)-citalopram (10mg/d)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 23622910

Group type: EXPERIMENTAL
Intervention: Coroflex Please
Number of subjects: 945

Group type: COMPARATOR
Intervention: Taxus Liberte
Number of subjects: 945
Study: 20864549

Group type: EXPERIMENTAL
Intervention: Weight management program with seven training sessions over 2.5 months
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 81
Study: 19112802

Group type: EXPERIMENTAL
Intervention: 2% mequinol (4‐hydroxyanisole, 4HA) and 0.01% tretinoin (Solagé) applied twice daily for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ethyl alcohol vehicle (control)
Number of subjects: 0
Study: 17267375

Group type: EXPERIMENTAL
Intervention: Structured Practice
Number of subjects: 14
Study: 12560952

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia exposure (OI) for 22 years
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia exposure (SI) for 6 months
Number of subjects: 2

Group type: COMPARATOR
Intervention: Residents at altitude (RA)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Soldiers at sea level (SL)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxia exposure (OI and SI)
Number of subjects: 2
Study: 10689271

Group type: EXPERIMENTAL
Intervention: Home-based, transtelephonically monitored cardiac rehabilitation
Number of subjects: 133

Group type: COMPARATOR
Intervention: Standard on-site rehabilitation
Number of subjects: 133
Study: 9338902

Group type: EXPERIMENTAL
Intervention: 10 mg intravenous metoclopramide
Number of subjects: 32

Group type: COMPARATOR
Intervention: Intravenous saline placebo
Number of subjects: 32
Study: 8415169

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement with daily application of sodium fluoride gel (pH 5.8)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Glass ionomer cement without topical fluoride
Number of subjects: 36
Study: 3535055

Group type: EXPERIMENTAL
Intervention: Oral norfloxacin (400 mg every 12 hours)
Number of subjects: 68
Study: 31967599

Group type: EXPERIMENTAL
Intervention: Quadriceps tendon (QT) autograft
Number of subjects: 28

Group type: COMPARATOR
Intervention: Hamstring tendon (HT) autograft
Number of subjects: 28
Study: 29367449

Group type: EXPERIMENTAL
Intervention: Zonisamide 50 mg once daily
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Zonisamide 25 mg once daily
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study: 28365440

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Lamotrigine (LTG)
Number of subjects: 66
Study: 25559913

Group type: EXPERIMENTAL
Intervention: Motivational interviewing intervention over 90 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (control group)
Number of subjects: 0
Study: 23428884

Group type: EXPERIMENTAL
Intervention: Treadmill training for 5 weeks (3 sessions/week)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Overground walking training for 5 weeks (3 sessions/week)
Number of subjects: 22
Study: 21561933

Group type: EXPERIMENTAL
Intervention: Neurofeedback (NF)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Standard computer format (SCF)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 41
Study: 18505757

Group type: EXPERIMENTAL
Intervention: Contact with a befriender facilitator and offer of match with a trained lay volunteer befriender
Number of subjects: 236

Group type: COMPARATOR
Intervention: No befriender facilitator contact (Control)
Number of subjects: 236
Study: 17348239

Group type: EXPERIMENTAL
Intervention: Current wheeze
Number of subjects: 7549

Group type: EXPERIMENTAL
Intervention: Past 12 months wheeze
Number of subjects: 7549

Group type: EXPERIMENTAL
Intervention: Self-reported asthma
Number of subjects: 7549

Group type: EXPERIMENTAL
Intervention: Current rhinitis
Number of subjects: 7549

Group type: EXPERIMENTAL
Intervention: Rhinoconjunctivitis
Number of subjects: 7549

Group type: EXPERIMENTAL
Intervention: Current chronic rash
Number of subjects: 7549

Group type: EXPERIMENTAL
Intervention: Chronic rash with flexural distribution
Number of subjects: 7549

Group type: EXPERIMENTAL
Intervention: Family history of allergy
Number of subjects: 7549

Group type: EXPERIMENTAL
Intervention: Concurrent rhinoconjunctivitis
Number of subjects: 7549

Group type: EXPERIMENTAL
Intervention: Concurrent chronic flexural rash
Number of subjects: 7549

Group type: EXPERIMENTAL
Intervention: Previous respiratory infection
Number of subjects: 7549
Study: 14674148

Group type: EXPERIMENTAL
Intervention: HRT + statin (Systen Sequi, Cilag + Zocor, MSD)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: HRT + statin (Systen Conti, Cilag + Zocor, MSD)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: statin only (Zocor, MSD)
Number of subjects: 75

Group type: COMPARATOR
Intervention: HRT (Systen Sequi, Cilag)
Number of subjects: 75

Group type: COMPARATOR
Intervention: HRT (Systen Conti, Cilag)
Number of subjects: 75
Study: 11127128

Group type: EXPERIMENTAL
Intervention: Soft contact lens (Hydron Zero 6) wear
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Self‐prepared cotton thread test (SP‐CTT)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: NITBUT and PRT tests
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Wetting values (combinations of NITBUT and SP‐CTT or NITBUT and PRT)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: SP‐CTT
Number of subjects: 55
Study: 8865706

Group type: EXPERIMENTAL
Intervention: 3 l. min(‐1) oxygen with face mask for the initial 3 hours
Number of subjects: 48

Group type: COMPARATOR
Intervention: Room air
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 3 l. min(‐1) oxygen inhalation through the face mask
Number of subjects: 48
Study: 1469341

Group type: EXPERIMENTAL
Intervention: Manipulation (high-velocity, low-amplitude thrust)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Mobilization (muscle energy technique)
Number of subjects: 100
Study: 6435655

Group type: EXPERIMENTAL
Intervention: Ro 15‐1788 (5 mg i.v.)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Ro 15‐3505
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31259655

Group type: EXPERIMENTAL
Intervention: FPS 100/50 μg once daily (QD)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: FPS 100/50 μg twice daily (BID)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: FPS 250/50 μg BID
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: FPS 500/50 μg BID
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 27905266

Group type: EXPERIMENTAL
Intervention: Breaks with stretching
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Breaks with dynamic movement
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Passive breaks
Number of subjects: 30
Study: 26977121

Group type: EXPERIMENTAL
Intervention: Standardised Fermented Papaya Gel (SFPG) applied intragingivally (7 g) for 15 minutes daily for 10 days
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (traditional pharmacologic/surgical protocols)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Standardised Fermented Papaya Gel (SFPG)
Number of subjects: 84
Study: 24131045

Group type: EXPERIMENTAL
Intervention: In-home cognitive training program
Number of subjects: 68

Group type: COMPARATOR
Intervention: Life story interview
Number of subjects: 68
Study: 22939114

Group type: EXPERIMENTAL
Intervention: Standardized grading of OCT images by CATT readers (2 independent readers and a senior reader)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Independent reading center team measurements of total thickness at the foveal center point
Number of subjects: 270
Study: 21186968

Group type: EXPERIMENTAL
Intervention: Psychostimulants (amphetamine)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Psychotropic treatment history
Number of subjects: 52
Study: 16936304

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pill (OCP) [ethinyl estradiol (E(2)) 30 microg + desogestrel 150 microg]
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Norethisterone 10 mg/day
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 17-betaE(2) 4 mg/day
Number of subjects: 93

Group type: COMPARATOR
Intervention: No pre-treatment
Number of subjects: 93
Study: 16392443

Group type: EXPERIMENTAL
Intervention: Ankle Stabilizing Orthosis (ASO)
Number of subjects: 15
Study: 11865342

Group type: EXPERIMENTAL
Intervention: Ultrasonically activated coagulated shears (UACS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Monopolar electrosurgery
Number of subjects: 40
Study: 11255520

Group type: COMPARATOR
Intervention: Placebo for 14 days, followed by full‐dose (10 mg) ramipril until day 90
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Low‐dose (0.625 mg) ramipril for 90 days
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Full‐dose ramipril for 90 days
Number of subjects: 352
Study: 9449057

Group type: EXPERIMENTAL
Intervention: Various local and nonlocal (distant) complementary healing methods
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo-controlled protocols
Number of subjects: 0
Study: 7949208

Group type: EXPERIMENTAL
Intervention: Fadrozole (CGS 16949A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letrozole (CGS 20267)
Number of subjects: 0
Study: 3109893

Group type: EXPERIMENTAL
Intervention: Ro 15-1788
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no antagonist)
Number of subjects: 0
Study: 29611407

Group type: EXPERIMENTAL
Intervention: Robot-Assisted Pedicle Screw Fixation (Robot-PSF)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Conventional Freehand Pedicle Screw Fixation (Conv-PSF)
Number of subjects: 78
Study: 28801421

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) group receiving 10 sessions of EA treatment over 4 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Sham EA group receiving sham EA at non-acupoints using non-penetrating Streitberger acupuncture needles with mock EA
Number of subjects: 45

Group type: COMPARATOR
Intervention: Usual care group not receiving EA treatment
Number of subjects: 45
Study: 25628424

Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass surgery (RYGB)
Number of subjects: 30
Study: 24122389

Group type: EXPERIMENTAL
Intervention: docetaxel/capecitabine (docetaxel: 75 mg/m2 on day 1; capecitabine: 1,650 mg/m2 on days 1–14 every 3 weeks)
Number of subjects: 477

Group type: COMPARATOR
Intervention: docetaxel alone (75 mg/m2 on day 1 every 3 weeks)
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: docetaxel/capecitabine
Number of subjects: 477

Group type: EXPERIMENTAL
Intervention: pre-treatment Ki67LI
Number of subjects: 477
Study: 21029339

Group type: EXPERIMENTAL
Intervention: Aliskiren 150 mg
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12000

Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Angiotensin receptor blockers
Number of subjects: 12000

Group type: COMPARATOR
Intervention: Thiazide diuretics
Number of subjects: 12000

Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 12000
Study: 18571985

Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Fibrinolysis
Number of subjects: 1572
Study: 16823593

Group type: EXPERIMENTAL
Intervention: Chemotherapy group treated with mitomycin C, 5‐fluorouracil (5‐FU), and HCFU
Number of subjects: 984

Group type: COMPARATOR
Intervention: Control group (no postoperative adjuvant chemotherapy)
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Chemotherapy group
Number of subjects: 984

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 984
Study: 12783913

Group type: EXPERIMENTAL
Intervention: 12.5 mg/d paroxetine CR
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: 25.0 mg/d paroxetine CR
Number of subjects: 165

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 165
Study: 10770448

Group type: EXPERIMENTAL
Intervention: Bupropion SR (100-300 mg/day)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Sertraline (50-200 mg/day)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Sertraline (50 mg/day)
Number of subjects: 248

Group type: COMPARATOR
Intervention: Sertraline
Number of subjects: 248
Study: 8814842

Group type: EXPERIMENTAL
Intervention: Laser ablation of the prostate
Number of subjects: 148

Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 148
Study: 1299708

Group type: EXPERIMENTAL
Intervention: 350 mg isoniazid (INH)
Number of subjects: 772

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Both groups (INH and placebo)
Number of subjects: 772
Study: 31048088

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (4000 IU/day)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29663513

Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 300
Study: 27376711

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sulphonylurea
Number of subjects: 0
Study: 24951609

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy (capecitabine or fluorouracil, plus cisplatin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study: 22021274

Group type: EXPERIMENTAL
Intervention: Gain-framed messages advocating skin self-examination (SSE)
Number of subjects: 169

Group type: EXPERIMENTAL
Intervention: Loss-framed messages advocating skin self-examination (SSE)
Number of subjects: 169
Study: 21047164

Group type: EXPERIMENTAL
Intervention: Mental health care services response to domestic violence
Number of subjects: 0
Study: 17593405

Group type: EXPERIMENTAL
Intervention: PT-StabEx (physiotherapy, spine stabilisation exercises)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: PT-Mixed (physiotherapy, mixed techniques)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Keep active (CONTROL)
Number of subjects: 159
Study: 16358878

Group type: EXPERIMENTAL
Intervention: Inosine pranobex (Groprinosin) 50 mg/kg b.w/day for 10 days in 3 following months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Garlic (Alliofil)
Number of subjects: 30
Study: 12218200

Group type: EXPERIMENTAL
Intervention: Pumicing prior to bonding with Right-On
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pumicing prior to bonding with Fuji II LC
Number of subjects: 60

Group type: COMPARATOR
Intervention: No pumicing prior to bonding with Right-On
Number of subjects: 60

Group type: COMPARATOR
Intervention: No pumicing prior to bonding with Fuji II LC
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Use of resin-modified glass poly(alkenoate) cement (Fuji II LC)
Number of subjects: 60
Study: 9856371

Group type: EXPERIMENTAL
Intervention: Calcium supplementation (25 mmol/day or 1 g/day of calcium as calcium carbonate)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control period (no calcium supplementation)
Number of subjects: 60
Study: 8557956

Group type: EXPERIMENTAL
Intervention: Short-term contact lens wear (30-hour period including overnight)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no recent contact-lens-wearing experience)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Neophyte group (8 subjects fitted with lenses)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Experienced group (6 contact lens wearers)
Number of subjects: 16
Study: 2212020

Group type: EXPERIMENTAL
Intervention: Peripheral streptomycin/lidocaine injections (S/L)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 17
Study: 38214

Group type: EXPERIMENTAL
Intervention: 200 mg labetalol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 400 mg labetalol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31549255

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI) 184/22 mcg or 92/22 mcg
Number of subjects: 775900

Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 775900

Group type: COMPARATOR
Intervention: Usual care (UC) with inhaled corticosteroids (ICS) alone or in combination with a long-acting β2-agonist (ICS/LABA)
Number of subjects: 775900
Study: 31237450

Group type: EXPERIMENTAL
Intervention: Upper body resistance exercise protocol (EX)
Number of subjects: 19

Group type: COMPARATOR
Intervention: 20-min rest (CON)
Number of subjects: 19
Study: 28558825

Group type: EXPERIMENTAL
Intervention: 8-week home-based exercise program in addition to usual care
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 140
Study: 26130237

Group type: EXPERIMENTAL
Intervention: Ubiquinol (200 mg enteral, twice a day for up to seven days)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo (twice a day for up to seven days)
Number of subjects: 38
Study: 24259599

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (DEX)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol (PRO)
Number of subjects: 30
Study: 21048514

Group type: EXPERIMENTAL
Intervention: 0.05% flunarizine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 18838149

Group type: EXPERIMENTAL
Intervention: Praziquantel plus artesunate
Number of subjects: 312

Group type: COMPARATOR
Intervention: Praziquantel plus placebo
Number of subjects: 312

Group type: COMPARATOR
Intervention: Artesunate plus placebo
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: All treatment regimens
Number of subjects: 312
Study: 17913695

Group type: EXPERIMENTAL
Intervention: Quick strategy (ICD implanted without EPS and pre-discharge test)
Number of subjects: 190

Group type: COMPARATOR
Intervention: Extensive strategy (EPS, extensive DFT-test, and pre-discharge test)
Number of subjects: 190

Group type: EXPERIMENTAL
Intervention: Quick strategy
Number of subjects: 190

Group type: COMPARATOR
Intervention: Both strategies
Number of subjects: 190
Study: 15041084

Group type: EXPERIMENTAL
Intervention: 0.5 mg sublingual testosterone
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 11281339

Group type: EXPERIMENTAL
Intervention: Lisinopril (20 mg/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (90 mg/day)
Number of subjects: 31
Study: 9134507

Group type: EXPERIMENTAL
Intervention: Individualized developmental care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual standard of nursery care (Control)
Number of subjects: 0
Study: 8201073

Group type: EXPERIMENTAL
Intervention: Behavioral therapy (flooding)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Atenolol
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study: 3295317

Group type: EXPERIMENTAL
Intervention: 45% BCAA intravenous solution
Number of subjects: 40

Group type: COMPARATOR
Intervention: 23% BCAA intravenous solution
Number of subjects: 40
Study: 30929570

Group type: EXPERIMENTAL
Intervention: Combined RIC and PostC in addition to primary PCI
Number of subjects: 696

Group type: COMPARATOR
Intervention: Conventional PCI (control)
Number of subjects: 696

Group type: EXPERIMENTAL
Intervention: PostC alone in addition to primary PCI
Number of subjects: 696
Study: 28729154

Group type: EXPERIMENTAL
Intervention: Tremelimumab (10 mg/kg) every 4 weeks for 7 doses and every 12 weeks thereafter until treatment discontinuation
Number of subjects: 571

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 571

Group type: EXPERIMENTAL
Intervention: Tremelimumab
Number of subjects: 571
Study: 25987645

Group type: EXPERIMENTAL
Intervention: Acupuncture (performed on 20 participants over 4 weeks, 3 times per week, each session lasting half an hour)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Clonazepam (20 patients took 0.5 mg once a day for 2 weeks, then 0.5 mg in the morning and evening for the next 2 weeks)
Number of subjects: 42
Study: 23372745

Group type: EXPERIMENTAL
Intervention: 3.36 g/d EPA and DHA
Number of subjects: 54

Group type: COMPARATOR
Intervention: Butter fat (control)
Number of subjects: 54
Study: 21515479

Group type: EXPERIMENTAL
Intervention: Volume-controlled ventilation (VCV) without positive end-expiratory pressure (PEEP) (VT=8 ml/kg, Rf=12/min)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation (PCV) with maintenance of an identical peak pressure (Ppeak) (Rf=12/min, PEEP=0)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Small tidal volume ventilation with PEEP (VT=6 ml/kg, Rf=16/min, PEEP=5 cm H(2)O)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (TLV)
Number of subjects: 30
Study: 19637348

Group type: EXPERIMENTAL
Intervention: Liposomal MTP‐PE
Number of subjects: 91

Group type: COMPARATOR
Intervention: Regimen A (3-drug chemotherapy without ifosfamide)
Number of subjects: 91
Study: 17303322

Group type: EXPERIMENTAL
Intervention: Awake surgery
Number of subjects: 53

Group type: COMPARATOR
Intervention: Surgery under general anesthesia (GA)
Number of subjects: 53
Study: 15185266

Group type: EXPERIMENTAL
Intervention: Life-skills promotion program (six-session school-based program)
Number of subjects: 258

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 258